What is the longest survival period of Carpiseti/Tunicade?

When discussing the efficacy of Capivasertib, patients and their families are often most concerned about "how long the longest survival period can be." This issue actually involves the long-term follow-up results of clinical studies as well as the accumulation of real-world data. As a new type of AKT inhibitor, carpiseti has shown the potential to delay disease progression and improve overall survival in indications such as advanced breast cancer, but the specific time of its longest survival is still under continuous observation.

In an international multi-center clinical trial, the combination of capicipositi and fulvestrant significantly prolonged progression-free survival compared with endocrine therapy alone. Although some studies have shown an improvement trend in overall survival rate, long-term follow-up data are still being accumulated due to the short time since the drug was approved. In other words, we can confirm that the drug does indeed bring a longer survival benefit, but to accurately answer"maximum survival", more years of observation and real-world evidence are needed.

The survival period of cancer treatment is not determined by the drug alone, but is the result of the interaction of multiple factors. The patient's genetic background, previous treatment history, comorbidities, and drug tolerance will all affect individualized survival time. Some patients can maintain stable disease for a longer period of time and have significantly improved quality of life after receiving carpisetin treatment; while other patients may shorten the time to benefit from treatment due to early onset of drug resistance or side effects. Therefore, instead of asking "how long can you live?", it is more important to understand the clinical value of capizetin, which is to provide patients with new means to delay progression and improve quality of life.

From the perspective of oncology development, the significance of carpisetig is not only to prolong the survival of individual patients, but also to provide a new mechanism for treatment. In the future, with the optimization of combination therapy and biomarker screening, the survival benefit of capicistat may be further improved.

Reference materials:https://www.drugs.com/mtm/capivasertib.html